Sandoz

Company Description

Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.

Analysis

ANALYSIS: With an Obermatt 360° View of 74 (better than 74% compared with alternatives), overall professional sentiment and financial characteristics for the stock Sandoz are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Sandoz. The consolidated Growth Rank has a good rank of 91, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 91% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 85, which means that professional investors are more optimistic about the stock than for 85% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 45, which means that the share price of Sandoz is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 55% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 24, which means that the company has a financing structure that is riskier than those of 76% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

Country

Switzerland

Industry Pharmaceuticals

Size X-Large

Website sandoz.com

Index

Add to Watchlist

See Similar Stocks

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.